Evidence map›Paper›PMID 21673100›Full record

ArticleEndocrinology2011

Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells.

Junyu Ning, Gang Xi, David R Clemmons

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 111 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Sexual dimorphic effects ofFrontiers in endocrinology · 2022
    Article
  12. Survival of HT29 Cancer Cells Is Affected by IGF1R InhibitionPathology oncology research : POR · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Junyu NingDepartment of Medicine, University of North Carolina, School of Medicine, Chapel Hill, North Carolina 27599, USA.
Gang Xi
David R Clemmons
University of North Carolina at Chapel Hill · USBeijing Center for Disease Prevention and Control · CN

Funding

Role of Integrins/ECM in Controlling IGF-I ActionsR37AG002331 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CLEMMONS, DAVID ROBERT · 2004 to 2013
$3.7M
THE EFFECT OF AGING ON HORMONAL CONTROL OF REPLICATIONR01AG002331 · NIA · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI CLEMMONS, DAVID ROBERT · 1985 to 2002
$1.0M
NIA NIH HHS AG02331NIA NIH HHS R01 AG002331NIA NIH HHS R37 AG002331
6 · The paper itself

Abstract

As a metabolic sensor, the serine/threonine protein kinase AMP-activated protein kinase (AMPK) promotes the adaptation of cells to signals arising from nutrients, hormones, and growth factors. The ability of IGF-I to stimulate protein synthesis is suppressed by AMPK, therefore, these studies were undertaken to determine whether IGF-I modulates AMPK activity. IGF-I dose-dependently suppressed phosphorylation of AMPK T172, and it stimulated AMPK S485 phosphorylation in vascular smooth muscle cells (VSMC). To determine whether stimulation of AMPK S485 phosphorylation was mediating this response, VSMC were transduced with a mutant AMPKα (AMPK S485A). Expression of this altered form inhibited the ability of IGF-I to suppress AMPK T172 activation, which resulted in inhibition of IGF-I-stimulated phosphorylation of P70S6 kinase. In contrast, expression of an AMPK S485D mutant resulted in constitutive suppression of AMPK activity and was associated with increased IGF-I-stimulated P70S6K phosphorylation and protein synthesis. The addition of a specific AKT inhibitor or expression of an AKT1 short hairpin RNA inhibited AMPK S485 phosphorylation, and it attenuated the IGF-I-induced decrease in AMPK T172 phosphorylation. Exposure to high glucose concentrations suppressed AMPK activity and stimulated S485 phosphorylation, and IGF-I stimulated a further increase in S485 phosphorylation and AMPK T172 suppression. We conclude that AMPK S485 phosphorylation negatively regulates AMPK activity by modulating the T172 phosphorylation response to high glucose and IGF-I. IGF-I stimulates S485 phosphorylation through AKT1. The results suggest that AMPK plays an inhibitory role in modulating IGF-I-stimulated protein synthesis and that IGF-I must down-regulate AMPK activity to induce an optimal anabolic response.

Indexed as

AMP-Activated Protein KinasesAnimalsCells, CulturedDiabetes Mellitus, ExperimentalEnzyme ActivationHyperglycemiaInsulin-Like Growth Factor IMaleMiceMice, Inbred C57BLMuscle, Smooth, VascularMyocytes, Smooth MusclePhosphoserineProto-Oncogene Proteins c-aktSwineAMP-Activated Protein KinasesInsulin-Like Growth Factor IPhosphoserineProto-Oncogene Proteins c-akt

Identifiers

PMID21673100
PMCPMC3138225
OpenAlexW2057180183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.